Innovating Targeted RNA Delivery

We are excited to share an interview published on Osservatorio Terapie Avanzate, where our CTO Prof. Elita Montanari discusses our innovative approach to targeted RNA delivery.

In the rapidly evolving field of RNA therapies, we believe that precision in delivery is key to enhancing both efficacy and safety. In the interview, we explore how our technology addresses current challenges, paving the way for more targeted and personalized treatments.

We invite you to read the full interview to discover how EVIS Bioscience is working to transform the future of advanced therapies:

➡️ An Innovative System for Targeted RNA Delivery – Osservatorio Terapie Avanzate

Lastest Posts

  • La Repubblica news article

    We are proud to share that EVis Bioscience has been featured in la Repubblica‘s “Lab Revolution” series, highlighting our innovative approach to gene therapy for rare diseases. Founded in June 2024 by Italian researchers Elita Montanari with investor Tommaso Caselli, EVis Bioscience is a spin-off from ETH Zurich. Our mission is to develop next-generation non-viral…

  • Exosome RNA news article

    A recent study published on Exosome RNA introduces a novel method for efficiently loading nucleic acids into extracellular vesicles (EVs). This technique involves the spontaneous hybridization of EVs with preloaded non-lamellar liquid crystalline lipid nanoparticles (LCNPs) under physiological conditions, resulting in the formation of hybrid extracellular vesicles (HEVs). Key findings from the study include: This…